A share price of Immunic Inc [IMUX] is currently trading at $0.98, down -0.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMUX shares have gain 1.86% over the last week, with a monthly amount glided 18.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on November 25, 2024, and set its price target to $10. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 27, 2024. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on October 21, 2022. In a note dated April 15, 2021, Aegis Capital initiated an Buy rating and provided a target price of $55 on this stock.
Immunic Inc experienced fluctuations in its stock price throughout the past year between $0.56 and $2.11. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.98 at the most recent close of the market. An investor can expect a potential return of 410.2% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -4.7, Equity is -3.27 and Total Capital is 19.89. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunic Inc [NASDAQ:IMUX] is 0.74. As well, the Quick Ratio is 0.74, while the Cash Ratio is 0.56.
Transactions by insiders
Recent insider trading involved Nash Duane, Executive Chairman, that happened on Jun 13 ’25 when 20000.0 shares were purchased. President and COO, Tardio Jason completed a deal on Jun 05 ’25 to buy 12512.0 shares. Meanwhile, CEO and Director Vitt Daniel bought 15000.0 shares on Jun 04 ’25.
